Non-small Cell Lung Carcinoma Clinical Trial
Official title:
Hypermetabolism in the Elderly Lung Cancer Patient
Aging and cancer are two conditions associated with extensive metabolic changes that can cause malnutrition. However, the clinical features and the underlying mechanisms leading to malnutrition are different in these two cases. We therefore wonder how age can influence the metabolic response to cancer.
During aging, among other physiological modifications, inactivity and insulin resistance
cause a progressive muscle loss associated with a decrease in resting energy expenditure
(REE). In cancer, loud inflammation background also provokes a decrease in muscle mass as
well as in fat mass. However, previous studies reported an increased REE, termed
hypermetabolism, probably linked to inflammation.
Data concerning response to aggression in the elderly patient is scarce and even inexistent
when it comes to cancer. The investigators hypothesize that the mitochondrial dysfunction
that comes with aging and that decreases the ATP rendering per unit of energy-producing
nutrient oxidized increases the amount of nutrient to be consumed in order to sustain to
energy needs. Therefore, in this situation, elderly patients could have a higher rate or
degree of hypermetabolism than younger patients.
The primary objective of this study is to assess the effect of aging on the metabolic
response to cancer assessed by resting energy expenditure measured by indirect calorimetry
corrected by whole body fat free mass calculated from single slice CT imaging at the third
lumbar vertebra.
The secondary objective of this study is to point out some inflammatory or endocrine
determinants of these energy metabolism changes in the cancer patient.
Non-small cell lung carcinoma seems to be a relevant choice for this study because it is
frequently associated with cachexia and the literature reports a high rate of
hypermetabolism in this cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05110196 -
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
|
Phase 4 | |
| Completed |
NCT02795156 -
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
|
Phase 2 | |
| Terminated |
NCT02556593 -
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT03678350 -
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
|
Phase 1 | |
| Recruiting |
NCT05358249 -
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02273271 -
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo
|
N/A | |
| Withdrawn |
NCT03408561 -
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
|
N/A | |
| Active, not recruiting |
NCT04984811 -
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
|
Phase 2 | |
| Completed |
NCT02922777 -
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
|
Phase 1 | |
| Active, not recruiting |
NCT01279408 -
Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)
|
||
| Completed |
NCT00081315 -
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03731585 -
Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment
|
N/A | |
| Active, not recruiting |
NCT02009449 -
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00540514 -
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05642195 -
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02848872 -
Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT06222489 -
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
|
Phase 2 | |
| Active, not recruiting |
NCT03752398 -
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
|
Phase 1 | |
| Terminated |
NCT01288430 -
A Study of DS-2248 in Participants With Advanced Solid Tumors
|
Phase 1 |